The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice.

ABSTRACT: Clostridioides difficile is the leading cause of antibiotic-associated intestinal infections. The pathogenesis of C. difficile infection (CDI) is driven by two protein exotoxins, TcdA and TcdB. The TcdB-targeting monoclonal antibody (mAb) bezlotoxumab (Zinplava) was indicated to reduce CDI recurrence in patients 18 years of age or older who are receiving antibacterial drug treatment for CDI and are at high risk for CDI recurrence. However, Zinplava has recently been discontinued, underscoring the need for additional therapeutics. AZD5148 is a humanized anti-TcdB mAb that neutralizes toxin activity by blocking the delivery of the enzymatic glucosyltransferase domain (GTD) into host cells. TcdB sequence variation influences receptor tropism and substrate specificity, with three major subtype

SUBMITTER: Peritore-Galve FC 

PROVIDER: S-EPMC12594360 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature